open access
Human Papillomavirus and the use of nanoparticles for immunotherapy in HPV-related cancer: A review
open access
Abstract
Human Papillomavirus (HPV) remains one of the most commonly contracted sexually transmitted diseases around the world. There are a multitude of HPV types, some of which may never present any symptoms. Others, however, are considered high-risk types, which increase the chance of the person infected to develop cancer. In recent years, the utilization of nanotechnology has allowed researchers to employ and explore the use of nanoparticles in immunotherapies.
The new nanoparticle frontier has opened many doors in this area of research as a form of prevention, diagnosis, and treatment in cancers resulting from HPV. This review will provide a brief background of HPV, its relationship to head and neck cancer (HNC) and present some insight into the field of immunotherapeutic nanoparticles.
Abstract
Human Papillomavirus (HPV) remains one of the most commonly contracted sexually transmitted diseases around the world. There are a multitude of HPV types, some of which may never present any symptoms. Others, however, are considered high-risk types, which increase the chance of the person infected to develop cancer. In recent years, the utilization of nanotechnology has allowed researchers to employ and explore the use of nanoparticles in immunotherapies.
The new nanoparticle frontier has opened many doors in this area of research as a form of prevention, diagnosis, and treatment in cancers resulting from HPV. This review will provide a brief background of HPV, its relationship to head and neck cancer (HNC) and present some insight into the field of immunotherapeutic nanoparticles.
Keywords
Cancer; HPV; HNC; Nanoparticle; Immunotherapy
About this articleTitle
Human Papillomavirus and the use of nanoparticles for immunotherapy in HPV-related cancer: A review
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
544-550
Published online
2019-11-01
DOI
10.1016/j.rpor.2019.08.006
Bibliographic record
Rep Pract Oncol Radiother 2019;24(6):544-550.
Keywords
Cancer
HPV
HNC
Nanoparticle
Immunotherapy
Authors
Michael Jakob Rupar
Pawel Golusinski
Wojciech Golusinski
Michal M. Masternak